{"id":"lar-lanreotide","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Abdominal pain"},{"rate":"15-25","effect":"Nausea"},{"rate":"15-20","effect":"Cholelithiasis (gallstones)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201184","moleculeType":"Protein","molecularWeight":"1156.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lanreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and normal endocrine tissues. This binding suppresses the release of growth hormone, insulin-like growth factor-1 (IGF-1), and other hormones, thereby controlling hormone-related symptoms and slowing tumor growth in neuroendocrine malignancies.","oneSentence":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:37.388Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"},{"name":"Carcinoid syndrome"}]},"trialDetails":[{"nctId":"NCT05364944","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2022-05-18","conditions":"Acromegaly, GEP-NET","enrollment":19},{"nctId":"NCT05050942","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2021-10-22","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":332},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":"Neuroendocrine Tumors","enrollment":51},{"nctId":"NCT03792555","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2019-03-11","conditions":"Acromegaly","enrollment":13},{"nctId":"NCT02736448","phase":"PHASE2","title":"177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-05","conditions":"Gastro-entero-pancreatic Neuroendocrine Tumors","enrollment":35},{"nctId":"NCT05701241","phase":"PHASE4","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-06-28","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":270},{"nctId":"NCT01538966","phase":"NA","title":"Acromegaly Combination Treatment Study","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-03-29","conditions":"Acromegaly","enrollment":76},{"nctId":"NCT02973204","phase":"","title":"Circulating Tumor Cells and Tumor DNA in HCC and NET","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-11","conditions":"Carcinoma, Hepatocellular, Neuroendocrine Tumors","enrollment":167},{"nctId":"NCT00092287","phase":"PHASE3","title":"Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","status":"TERMINATED","sponsor":"Ipsen","startDate":"2004-07","conditions":"Malignant Carcinoid Syndrome","enrollment":4},{"nctId":"NCT00444873","phase":"PHASE3","title":"Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly","status":"COMPLETED","sponsor":"Ipsen","startDate":"2005-01","conditions":"Acromegaly","enrollment":38},{"nctId":"NCT00216398","phase":"PHASE4","title":"Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR","status":"COMPLETED","sponsor":"Ipsen","startDate":"2004-06","conditions":"Acromegaly","enrollment":8},{"nctId":"NCT02396953","phase":"PHASE1, PHASE2","title":"Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly","status":"COMPLETED","sponsor":"Ipsen","startDate":"2015-03","conditions":"Acromegaly","enrollment":28},{"nctId":"NCT00701363","phase":"PHASE4","title":"Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects","status":"COMPLETED","sponsor":"Ipsen","startDate":"2008-10","conditions":"Acromegaly","enrollment":124},{"nctId":"NCT03017690","phase":"","title":"Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2017-04-12","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":22},{"nctId":"NCT01137682","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07-19","conditions":"Acromegaly","enrollment":198},{"nctId":"NCT02668172","phase":"PHASE4","title":"Pasireotide LAR and Pegvisomant Study in Acromegaly","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-08","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT00495846","phase":"PHASE2, PHASE3","title":"GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Federico II University","startDate":"2007-04","conditions":"Advanced Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT00703079","phase":"","title":"Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly","status":"COMPLETED","sponsor":"Federico II University","startDate":"1997-01","conditions":"Acromegaly","enrollment":100},{"nctId":"NCT00615004","phase":"","title":"Cardiovascular Outcome After Surgery or Somatostatin Analogues","status":"COMPLETED","sponsor":"Federico II University","startDate":"1997-01","conditions":"Acromegaly","enrollment":215},{"nctId":"NCT00145405","phase":"PHASE4","title":"Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2002-09","conditions":"Acromegaly","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":165,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"LAR Lanreotide","genericName":"LAR Lanreotide","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones. Used for Acromegaly, Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Carcinoid syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}